This review evaluates Organ-on-a-Chip efforts published over the last two years in light of end-user adoption aspects.
In this webinar, MIMETAS and Molecular Devices present OrganoPlates® as a novel microfluidic culture platform enabling long-term, membrane-free 3D co-culture models in a microtiter plate format.
On December 9, 2016 our paper on 3D neuronal cultures in OrganoPlates was published in Nature Scientific Reports.
The NIH has awarded MIMETAS and the University of Pittsburgh a prestigious SBIR grant to develop a Liver-on-a-Chip platform for high throughput discovery and development.
MIMETAS, Galapagos, (Euronext & NASDAQ: GLPG), and University of Sheffield, have embarked on a collaboration to develop an Inflammatory Bowel Disease (IBD) model in MIMETAS’ OrganoPlates®.
In the 1.5mn euro HepaPlate™ project, MIMETAS will develop an organ-on-a-chip hepatotoxicity-screening platform for toxicological evaluation of small molecules.
The Horizon 2020 project CoSTREAM aims to improve our understanding of the co-occurrence of stroke and Alzheimer’s disease. The consortium builds upon an extensive infrastructure of longitudinal follow-up studies. These studies have data on both diseases as separate clinical outcomes, and contain information on a broad range of aetiological factors ranging from genetics and metabolomics to brain structure and function.
In this review we address the application of state-of-the-art microfluidic culturing techniques, with a focus on culturing kidney proximal tubules, that are promising for the detection of biomarkers that predict drug interactions and toxicity.
MIMETAS takes part in a new Parkinson's project to identify drugs that slow down neurodegeneration in PD patients with overt mitochondrial dysfunction.
Paul Vulto in article in Nature of July 16, 2015 by Sara Reardon entitled "Organs-on-chips go mainstream", also quoting Adrian Roth from Roche and Matthew Wagoner from AstraZeneca.